GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Research & Development

Affymax, (FRA:A5Y) Research & Development : €-0.09 Mil (TTM As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Affymax, Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Affymax,'s Research & Development for the three months ended in Jun. 2014 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2014 was €-0.09 Mil.

Affymax, Research & Development Historical Data

The historical data trend for Affymax,'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Research & Development Chart

Affymax, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 107.79 70.79 57.99 39.42 8.66

Affymax, Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 -0.12 0.04 - -

Affymax, Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affymax,  (FRA:A5Y) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Affymax, Research & Development Related Terms

Thank you for viewing the detailed overview of Affymax,'s Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax, (FRA:A5Y) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Research & Development
Comparable Companies
TSXV:APC APOP BOM:532871 ONTX BTHE TSXV:PBS GLPH BRTX AURX PTEO AKAOQ TIKRF NVIV ATMS CAPS HSTC TSXV:COT BOM:542765 TSXV:MFS RSPI
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Website
http://www.affymax.com
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines